Clinical trials: PD-1 Inhibitors
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a single-center, single-arm, phase II clinical trial designed to evaluate the efficacy and safety of becotatug vedotin combined with gemcitabine and a PD-1 inhibitor as second-line or later treatment for patients with…
- Trial name
- NCT07902713
- Testing
- Becotatug Vedotin (MRG003), Gemcitabine (1000 mg/m2), Camrelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Advanced Non Small Cell Lung Cancer
Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
This open-label, multicenter, dose-escalation and expansion trial is designed to evaluate the safety and preliminary efficacy of inhaled DV281 in combination with nivolumabfor the treatment of NSCLC and to select a recommended…
- Trial name
- NCT03326752
- Testing
- DV281, Breath Actuated Nebulizer, DV281 (RP2D)
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dynavax Technologies Corporation
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy
The aim of this study is to define the efficacy and safety of Fluzoparib and Camrelizumab in treating patients with recurrent/metastatic nasopharyngeal carcinoma that progressed after first-line chemotherapy.
- Trial name
- NCT04978012
- Testing
- Fluzoparib and Camrelizumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma
Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy
Advanced esophageal squamous cell carcinoma patients who have failed first-line PD-1 inhibitor combined with chemotherapy lack a standard treatment option.
- Trial name
- NCT05990231
- Testing
- Cadonilimab combined Anlotinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colo-rectal Cancer, PD-1 Inhibitor
Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer
The investigators propose to conduct a single-center, single-arm, Phase I clinical study to explore the safety and feasibility of Akkermansia probiotics combined with anti-PD-1 monoclonal antibody in patients with MSS/pMMR…
- Conditions
- Colo-rectal Cancer, PD-1 Inhibitor, Akkermansia Muciniphila
- Trial name
- NCT06865521
- Testing
- Akkermansia Probiotics
- Where
- 2 sites in China
- Volunteers
- 22 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma Non-resectable
Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004)
This study aims to evaluate the safety and efficacy of fecal microbiota transplantation (FMT) in reversing drug resistance to the triple therapy regimen in patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT06643533
- Testing
- Fecal Microbiota Transplantation
- Volunteers
- 15 people
- Sponsor
- Fujian Provincial Hospital
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC
The goal of this clinical trial is to evaluate if adding chemotherapy and immunotherapy as induction treatment prior to definitive chemoradiotherapy could improve the outcomes of locally advanced HPV-negative head and neck…
- Trial name
- NCT07776340
- Testing
- Tislelizumab, Paclitaxel, Cisplatin (75 mg/m2)
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Fudan University
Liver Cancer
Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
This trial was designed to investigate the survival outcomes, response rates, and safety of patients with Barcelona-Clinical Hepatocellular Carcinoma (BCLC)-C-stage liver cancer by hepatic artery versus vein infusion of…
- Trial name
- NCT03949231
- Testing
- PD1/PDL1 inhibitor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma, Liver Transplantation
Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant
This is a perspective clinical study to assess the safety and efficacy of PD-1 inhibitors in patients with LT. Eligible patients have recurrent or metastatic cancer after LT, are not amenable to, or refractory after, locoregional…
- Trial name
- NCT03966209
- Testing
- JS001(PD-1 inhibitor)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Zhongshan Hospital
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma
- Trial name
- NCT04375384
- Testing
- Cetuximab, Questionnaire administration, Quality of life assessment
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Wake Forest University Health Sciences
the Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced Melanoma
PD-1 Inhibitors With or Without Radiation in Advanced Melanoma
This trial was a single-center, prospective, randomized controlled phase II trial. The objective was to evaluate the efficacy and safety of PD-1 inhibitors with or without radiotherapy in patients with advanced melanoma.
- Trial name
- NCT05498805
- Testing
- Radiation
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Fudan University
Esophageal Cancer
Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced or Recurrent Esophageal Squamous Cell Carcinoma
The goal of this observational study is to to determine whether patients with a high proportion of precursor exhausted T cells (Tpex) in negative tumor draining lymph nodes have longer overall survival.
- Trial name
- NCT07533357
- Volunteers
- 158 people
- Sponsor
- Fudan University
Hypopharyngeal Carcinoma
Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma
This is a multi-center, randomized controlled, prospective clinical study.
- Trial name
- NCT07248956
- Testing
- Finolizumab, Albumin-Bound Paclitaxel /nab-Paclitaxel, Cisplatin
- Where
- 7 sites in China
- Volunteers
- 116 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Gastric Cancer, GastroEsophageal Cancer
Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer
This is a Multi-center, Open-label, Randomized Controlled,phase 2 clinical trail of Albumin-bound Paclitaxel Plus SHR-1210 （PD-1 inhibitor）Versus Albumin-bound Paclitaxel as Second-line Treatment in Advanced or Recurrent Gastric…
- Trial name
- NCT04294784
- Testing
- Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound Paclitaxel
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Huazhong University of Science and Technology
Malignant Melanoma Stage III
SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma
At present two studies (SWOG S1801 and NADINA) have demonstrated superiority when using neoadjuvant treatment compared to adjuvant treatment only, but no studies have compared PD-1 monotherapy (SWOG 1801 regimen) to the…
- Trial name
- SWE-NEO (NCT06794775)
- Testing
- Nivolumab, Nivolumab + Ipilimumab
- Where
- 3 sites in Sweden
- Volunteers
- 128 people
- Sponsor
- Hildur Helgadottir
Colon Cancer
Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients
The goal of this clinical trial is to learn about efficacy of Rimegepant in combination with PD-1 in patients with liver metastasis colorectal cancer.
- Trial name
- NCT06999252
- Testing
- Rimegepant, PD-1
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Locally Advanced Rectal Cancer
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
This is a multicenter, prospective, randomized controlled study to evaluate the effectiveness and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and PCSK9 inhibitor in the treatment of patients with pMMR/MSS…
- Trial name
- NCT06304987
- Testing
- Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor, Long-course chemoradiation and PD-1 inhibitor, without PCSK9 inhibitor
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Beijing Friendship Hospital
Biliary Tract Cancer
Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs
This is a single-arm, phase I/II trial in biliary tract cancer (BTC) patients. The purpose of this trial is to evaluate the safety and effect of PD-1 inhibitor in combination with gemcitabine/cisplatin chemotherapy in patients…
- Trial name
- NCT03311789
- Testing
- PD-1 inhibitor + Gemcitabine + Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Head and Neck Squamous Cell Carcinoma
Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC
Patients with locally advanced (stage III to stage IVB) poorly differentiated head and neck squamous cell carcinoma (excluding nasopharyngeal carcinoma) who meet the inclusion criteria will have their blood samples collected…
- Trial name
- NCT06100497
- Testing
- Pembrolizumab, Cisplatin, Paclitaxel-albumin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing Tongren Hospital